Beraprost Sodium Tablets

This product is a derivative of prostacyclin (PGI2). Among the various humoral factors synthesized by the blood vessel wall, prostacyclin (PGI2) is the first substance on the market that can regulate vascular tension and plays an important role in maintaining blood flow in various tissues. It is the final product of the arachidonic acid chain reaction and has a strong anti-platelet aggregation and vasodilation effect. It is mainly produced by the metabolism of arachidonic acid in the blood vessel wall. Not only vascular endothelial cells but also vascular smooth muscle cells can produce PGI2. It has a strong vasodilation effect. It is now known that the synthesis of PGI2 in blood vessels in arteriosclerosis sites is reduced. It has been reported that the FGI2 stabilizing factor apolipoprotein A-Ⅰ is reduced in patients with ischemic heart diseases and acute myocardial infarction and unstable angina associated with coronary artery spasm. PGI2 has an exoenol ether structure. Because of its extremely unstable chemical properties, it decomposes rapidly in neutral solutions and in the body, so it is limited to diseases that can be intravenously dripped. This product replaces the exoenol structure with phenol and chemically modifies the ω side chain to enhance its activity and stability. This product is an oral prostacyclin derivative with strong vasodilatory and antiplatelet aggregation effects.

The main ingredient of this product is beraprost sodium, and its chemical name is: (±)-2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butyric acid sodium

The 20μg specification of this product is a white to off-white film-coated tablet with "BS20" engraved on one side, which appears white after the coating is removed; the 40μg specification is a light yellow film-coated tablet with "BS40" engraved on one side, which appears white after the coating is removed.

Chronic arterial occlusive diseases such as Raynaud's disease, Raynaud's syndrome, chronic cerebral infarction and other chronic arterial occlusive diseases.

40 mu g orally 3 times a day, 6 weeks as a course of treatment. Adults take 120 mu g per day, divided into 3 times after meals.

Occasionally, there are allergic reactions, headache, nausea, diarrhea, loss of appetite, increased liver function, facial flushing, palpitations, etc. Bleeding tendency includes cerebral hemorrhage, gastrointestinal bleeding, fundus hemorrhage, etc.; as well as facial flushing, headache, etc.

Pregnant women and patients with bleeding disorders are prohibited from taking this medicine. The following patients should take the medicine with caution: patients who are taking anticoagulants, antiplatelet drugs, thrombolytic agents; women during menstruation; patients with bleeding tendency and its factors.

Precautions for children: The safety of children taking the drug has not been established (no experience). Precautions for pregnancy and lactation: Pregnant women should not take the drug, and women during menstruation should use it with caution. Precautions for the elderly: Elderly patients should pay attention to the dosage when taking the drug (generally, the physiological functions of the elderly are reduced).

Not yet clear.

Keep away from light and store in airtight container.

20 micrograms

24 months

Beijing Tide Pharmaceutical Co., Ltd.

• Founded in:

  1995-05-29

• Address:

  No. 8 Rongjing East Street, Beijing Economic and Technological Development Zone, Beijing

• Tax NO.:

  911103026000314683

• Registered Funds:

  500 million yuan

• Website:

  Log in to view

• Email:

  Log in to view